It is all personal guesses of course but I wouldn’t expect that Roquefort, or indeed any other company, would be looking to purchase 100% of Lyramid. Certainly not at this stage anyway. The reason I say this is because I don’t believe any company would be looking to undertake the development of the full range of potential drug products that is represented by the Midkine and Midkine antibodies areas of relevance.
I would see the Provelmare/Lyramid arrangement as essentially a facilitator arrangement whereby Provelmare will fund the Phase I developments. If the Phase I, and possibly some Phase II work is positive individual drug companies that specialise in a particular relevant drug area might then look to a sub-licensing arrangement relevant to their specific interest or interests. I have illustrated that earlier in a post referring to the field of Oncology.
Lyramid may well develop one or more drugs of its own but I would expect most of their ‘products’ are going to relate to sub-licensing agreements.
poorinvestor
- Forums
- ASX - By Stock
- Ann: Agreement Signed for Sale of Lyramid Limited
It is all personal guesses of course but I wouldn’t expect that...
-
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $8.397K | 1.053M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1111500 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 36716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1111500 | 0.007 |
4 | 606527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
1 | 600000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 36716 | 1 |
0.009 | 340000 | 1 |
0.010 | 157763 | 1 |
0.011 | 100000 | 1 |
0.012 | 100000 | 1 |
Last trade - 15.46pm 18/07/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |